Aurinia Pharmaceuticals (AUPH) Change in Accured Expenses (2020 - 2026)

Aurinia Pharmaceuticals (AUPH) has 7 years of Change in Accured Expenses data on file, last reported at -$5.6 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 76.11% year-over-year to -$5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.2 million (up 715.15% YoY) and the FY2025 annual result came in at -$4.7 million, down 134.92% from the prior year.
• Change in Accured Expenses fell to -$5.6 million in Q1 2026, from $13.1 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $17.5 million in Q4 2024 to a low of -$23.4 million in Q1 2025.
• A 5-year average of $984000.0 and a median of $462000.0 in 2022 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses surged 5931.36% — and 2025, when it sank 194.92%.
• Tracing AUPH's Change in Accured Expenses over 5 years: stood at $616000.0 in 2022, then slumped by 44.48% to $342000.0 in 2023, then jumped by 5007.89% to $17.5 million in 2024, then fell by 24.88% to $13.1 million in 2025, then plunged by 142.62% to -$5.6 million in 2026.
• The last three Change in Accured Expenses figures came in at -$5.6 million (Q1 2026), $13.1 million (Q4 2025), and -$641000.0 (Q3 2025), per Business Quant data.